Caricamento...
Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2
Medical treatment has progressed significantly over the past decade towards achieving and maintaining clinical remission in patients with refractory ulcerative colitis (UC). Proposed mediators of inflammation in UC include pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interl...
Salvato in:
| Pubblicato in: | World J Gastroenterol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Baishideng Publishing Group Inc
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4528020/ https://ncbi.nlm.nih.gov/pubmed/26269667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i29.8776 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|